Ann Pharmacol Pharm | Volume 2, Issue 3 | Review Article | Open Access

Antibody Drug Conjugates: A New Era in Personalized Medicine and Targeted Cancer Therapy

Samaresh Sau and Arun K Iyer^*

Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, USA

^*Correspondance to: Arun K Iyer 

Fulltext PDF

Abstract

The challenges in discovery and development of small molecule drug has led to the emergence of antibody drug conjugates (ADCs) as an alternative for targeted cancer therapy. Over the past two decades, several antigens that have selective over expression on cancer cell surface have been identified and they have been exploited for tumor specific cargo delivery. Specific antibodies can be engineered to function as small molecule targeting ligand that can bind tightly to tumor cell’s over expressing the target antigen. The potential of ADCsrepresentsa novel class of cancer cell specific antigen targeted chemotherapy agent. ADCsthus represent a significant step forward in the war against cancer and personalized medicine.

Keywords:

Antibody drug conjugates (ADCs); Antibody; Drug conjugates; Criteria for ADCs; Over expressed antigen; Personalized cancer therapy; Personalized medicine

Citation:

Sau S, Iyer AK. Antibody Drug Conjugates: A New Era in Personalized Medicine and Targeted Cancer Therapy. Ann Pharmacol Pharm. 2017; 2(3): 1032.